STAMFORD, Conn.--(BUSINESS WIRE)--April 21, 2005--Marc Pharmaceuticals, Inc. (OTC:MPMA) (OTC:MPMAW) (OTC:MPMAZ) today announced the appointment of Michael G. Palfreyman, Ph.D., D.Sc. as a consultant and chief scientific and development advisor. Dr. Palfreyman has had more than 30 years of experience in the biotechnology and pharmaceutical industries. In addition to his work on behalf of Marc, Palfreyman remains head of development at EnVivo Pharmaceuticals. He also co-founded two biotechnology and consulting companies, Psychiatric Genomics, Inc. and NOVACE Corporation and held executive and scientific leadership positions in other biotechnology and pharmaceutical companies including Scriptgen (Anadys) Pharmaceuticals, Marion Merrell Dow (Sanofi-Aventis) and Beecham Pharmaceuticals (GlaxoSmithKline).
